Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
atectura breezhaler 150/80 μg capsule polvere per inalazione
novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - capsule polvere per inalazione - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.080 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
atectura breezhaler 150/160 μg capsule polvere per inalazione
novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - capsule polvere per inalazione - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.160 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
atectura breezhaler 150/320 μg capsule polvere per inalazione
novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - capsule polvere per inalazione - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.320 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika
Unione Europea -
italiano -
EMA (European Medicines Agency)
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - asma - farmaci per le malattie respiratorie ostruttive, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Unione Europea -
italiano -
EMA (European Medicines Agency)
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - asma - farmaci per le malattie respiratorie ostruttive, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.